Jeffrey W. Sherman - 28 Aug 2025 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Reporting relationship: Director
Issuer ticker: XERS
Reported as of: 28 Aug 2025
Net transaction value: -$21,229
SEC form: 4
Accepted by SEC: 29 Aug 2025, 17:21:38 UTC
Prior SEC filing: 04 Jun 2025
Next SEC filing: 02 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Beth Hecht, Attorney-in-Fact

Key filing fact

Jeffrey W. Sherman filed Form 4 for Xeris Biopharma Holdings, Inc. (XERS) on 29 Aug 2025.

Key facts

This page summarizes Jeffrey W. Sherman's Form 4 filing for Xeris Biopharma Holdings, Inc. (XERS).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 29 Aug 2025, 17:21.

Change

Previous filing in this sequence was filed on 04 Jun 2025.
Current net transaction value: -$21,229.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001230482 Primary reporting owner

SHERMAN JEFFREY W

Relationship: Director
Address: C/O XERIS BIOPHARMA HOLDINGS, INC., 1375 WEST FULTON STREET, SUITE 1300, CHICAGO
Signature: /s/ Beth Hecht, Attorney-in-Fact
Signature date: 29 Aug 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

XERS transaction

Common Stock

Options Exercise

Transaction value: $313,286
Shares: +47,040
Change %: +22%
Price: $6.66
Shares after: 261,420
Date: 28 Aug 2025
Ownership: Direct

XERS transaction

Common Stock

Sale

Transaction value: $334,515
Shares: -42,232
Change %: -16%
Price: $7.92
Shares after: 219,188
Date: 28 Aug 2025
Ownership: Direct
Footnotes: F1

XERS holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 5,400
Date: 28 Aug 2025
Ownership: By: JEFFREY W SHERMAN LIVING TRUST U/A DTD 03/21/2001
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

XERS transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -47,040
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 28 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 47,040
Exercise price: $6.66
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.920 to $7.935, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Footnote F2

The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Footnote F3

On October 1, 2016, the reporting person was granted an option to purchase shares of Strongbridge Biopharma plc ("Strongbridge") which were assumed by Issuer in connection with the acquisition of Strongbridge. The options vested in full on October 5, 2021.